A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Clinical trial NCT06427941 · RECRUITING

Trial details

NCT number: NCT06427941
Sponsor: BeOne Medicines
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Hepatocellular Carcinoma Local Advanced Hepatocellular Carcinoma Alpha-fetoprotein (AFP)-Producing Gastric Cancer Extragonadal Yolk Sac Tumors Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Start date: 2024-07-23
Primary completion: 2028-05-30
Enrollment: 392

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.